Skip to content

Study on the technology and clinical application of platelet cryopreservation at 4 degrees C

Study on the technology and clinical application of platelet cryopreservation at 4 degrees C

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000036353
Enrollment
Unknown
Registered
2020-08-22
Start date
2020-09-01
Completion date
Unknown
Last updated
2020-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Active bleeding and low platelet counts

Interventions

Experimental group:Cryopreservation of platelets at 4 degrees C
control group:Platelets preserved at 22 degrees C

Sponsors

Shaanxi Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Trauma and surgical bleeding are the main patients, aged 18 to 60 years old; (2) Patients with obstetric hemorrhage; (3) Voluntary signing of informed consent for transfusion and cryopreservation of platelets.

Exclusion criteria

Exclusion criteria: (1) Exclude patients with coagulation dysfunction caused by coagulation factor deficiency; (2) Patients taking antiplatelet drugs for a long time; (3) Patients with hypercoagulable diseases such as myocardial infarction and stroke; (4) Patients with severe multiple organ failure; (5) Patients with severe surgical trauma are expected to die within 24 hours; (6) Patients with postpartum hemorrhage complicated with severe liver and kidney failure; (7) The researcher thinks that it is not suitable for the patients; (8) Participants in other clinical trials; (9) Drug abuse, medical, psychological or social conditions that may interfere with the subjects' participation in research or evaluation of research results; (10) Epilepsy, dementia, or other spirits that need medical treatment cannot understand or comply with the research plan; (11) Patients with severe infectious diseases (incurable tuberculosis, pulmonary aspergillus) and aids.

Design outcomes

Primary

MeasureTime frame
Coagulation index;Platelet number;wound drainage;

Countries

China

Contacts

Public ContactJiangcun Yang

Department of Transfusion Medicine, Shaanxi Provincial People's Hospital

yjc65@sina.com+86 13571880512

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026